The estimated Net Worth of Marco Maria Brughera is at least $139 mil dollars as of 16 December 2016. Marco Brughera owns over 2,000 units of Fennec Pharmaceuticals Inc stock worth over $14,465 and over the last 11 years he sold FENC stock worth over $0. In addition, he makes $124,152 as Independent Director at Fennec Pharmaceuticals Inc.
Sign up
Marco Brughera FENC stock SEC Form 4 insiders trading
Marco has made over 2 trades of the Fennec Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of FENC stock worth $6,320 on 16 December 2016.
The largest trade he's ever made was exercising 7,500 units of Fennec Pharmaceuticals Inc stock on 5 August 2014 worth over $15,075. On average, Marco trades about 679 units every 62 days since 2013. As of 16 December 2016 he still owns at least 2,750 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Marco Brughera stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marco Brughera biography
Dr. Marco Maria Brughera serves as Independent Director of the Company. He has held several positions for the Sigma-Tau Group, including CEO and Global Head of Sigma Tau Rare Disease, President of Sigma-Tau Research and President of Sigma-Tau Pharmaceuticals. He drove the commercial revival of a lead oncology product line resulting in its successful sale for a total of around $900M USD. He also successfully out-licensed the Defibrotide US rights to Jazz Pharmaceuticals to Baxalta for a total value exceeding $1 billion USD. From 2004 to 2010, Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development company. He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group. From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer. Prior to 1999, he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company. He currently serves on the Board of Solgenix and Lee's Pharmaceutical and until early 2014 was a member of the Board of Gentium SpA. Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist.
What is the salary of Marco Brughera?
As the Independent Director of Fennec Pharmaceuticals Inc, the total compensation of Marco Brughera at Fennec Pharmaceuticals Inc is $124,152. There are 8 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.
How old is Marco Brughera?
Marco Brughera is 63, he's been the Independent Director of Fennec Pharmaceuticals Inc since 2016. There are 2 older and 6 younger executives at Fennec Pharmaceuticals Inc. The oldest executive at Fennec Pharmaceuticals Inc is Anne McKay, 67, who is the Regulatory Consultant.
Insiders trading at Fennec Pharmaceuticals Inc
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En..., eRosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
What does Fennec Pharmaceuticals Inc do?
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
What does Fennec Pharmaceuticals Inc's logo look like?
Complete history of Marco Brughera stock trades at Soligenix Inc e Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc executives and stock owners
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Rostislav Raykov,
Chief Executive Officer, Director -
Shubh Goel,
Chief Commercial Officer -
Robert Andrade,
Chief Financial Officer -
Rostislav Raykov,
CEO & Director -
Shubh Goel,
Chief Commercial Officer -
Robert C. Andrade,
Chief Financial Officer -
Khalid Islam,
Independent Chairman of the Board -
Chris Rallis,
Independent Director -
Adrian Haigh,
Independent Director -
Marco Brughera,
Independent Director -
Jodi Cook,
Independent Director -
Alexander D. Smith M.S.,
Consultant -
Anne McKay,
Regulatory Consultant -
Lei Fang,
Pres of Pharstat Inc -
Mark Gowland,
Controller -
Management Pr, Llcmancheste...,
-
Management Co Llc Mancheste...,
-
Spacavazza Paolo Cavazza En...,
-
Capital Advisors Lp Southpo...,
-
Jeffrey S. Hackman,
Chief Executive Officer -
Rosty Raykov,